Evidence map›Paper›PMID 22438498›Full record

ArticleProceedings. Biological sciences2012

How do antigenically varying pathogens avoid cross-reactive responses to invariant antigens?

Philip L F Johnson, Beth F Kochin, Rafi Ahmed, Rustom Antia

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings. Biological sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Frontiers in immunology · 2017
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Philip L F JohnsonDepartment of Biology, Emory University, Atlanta, GA, USA. plfjohnson@emory.edu
Beth F Kochin
Rafi Ahmed
Rustom Antia
Emory University · US

Funding

Targeting the PD-1 signaling pathway to rescue HIV T cell dysfunctionP01AI080192 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI · 2008 to 2012
$12.6M
T CELL MEMORY TO VIRUSESR01AI030048 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AHMED, RAFI · 1990 to 2022
$5.2M
Quantititive models of CD8+ immune memoryR01AI049334 · NIAID · EMORY UNIVERSITY · PI ANTIA, RUSTOM NOSHIR · 2001 to 2011
$1.6M
NIAID NIH HHS P01 AI080192NIAID NIH HHS R01 AI030048NIAID NIH HHS R01 AI049334
6 · The paper itself

Abstract

Pathogens such as trypanosomes and malaria use antigenic variation to evade immune responses and prolong the duration of infections. As pathogens typically express more than one antigen, even relatively rare conserved antigens might be expected to trigger cross-reactive immune responses capable of clearing the infection. We use simple mathematical models that explicitly consider the dynamic interplay between the replicating pathogen, immune responses to different antigens and immune exhaustion to explore how pathogens can escape the responses to both variable and invariant (conserved) antigens. Our results suggest two hypotheses. In the first, limited quantities of invariant antigens on each pathogen may lead to saturation in killing by cross-reactive responses. In the second, antigenic variation of the dominant antigens prolongs the duration of infection sufficiently to allow for exhaustion of the cross-reactive responses to subdominant, invariant epitopes prior to their being able to control the infection. These hypotheses make distinct predictions: the former predicts that cross-reactive responses will always be ineffective while the latter predicts that appropriately timed treatment could, by preventing exhaustion, lead to the generation of long-lasting protective cross-reactive immunity and thus act similarly to a vaccine.

Indexed as

Models, BiologicalAnimalsAntibodies, ProtozoanAntigenic VariationAntigensCross ReactionsHost-Parasite InteractionsParasitic DiseasesPlasmodiumTrypanosoma brucei bruceiTrypanosoma cruziAntibodies, ProtozoanAntigens

Identifiers

PMID22438498
PMCPMC3367775
OpenAlexW2116745967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.